Repository navigation
41_PHARMA_REMAINING
Date: 2026-08-22 Agent: Cage Sleuth Agent 88 Methodology: SEC EDGAR metadata-first investigation, phi-spaced search
This document catalogs publicly disclosed offshore and international subsidiary structures for 10 major pharmaceutical companies, sourced from SEC EDGAR filings (10-K, 20-F, EX-21 exhibits). All data is from publicly filed documents. No private or confidential information is included.
Key Finding: Ireland, Bermuda, Cayman Islands, Switzerland, Singapore, Puerto Rico, and the Netherlands are the primary jurisdictions used by these companies for international holding structures, IP management, and financing operations.
SEC CIK: 0000310158 Jurisdiction: Delaware, USA Primary Offshore Hubs: Ireland, Cayman Islands, Bermuda, Switzerland, Singapore
| Entity | Purpose |
|---|---|
| Schering-Plough Investments Cayman Ltd. | Investment holding |
| Lexington Biopharma II Limited | Biopharma investments |
| Entity | Purpose |
|---|---|
| Merck Sharp & Dohme (Ireland) (Human Health) Limited | IP holding, operational |
| MSD Shared Business Services EMEA Limited | Shared services |
| MSD Cubist Holdings Unlimited Company | Acquired entity holding |
| MSDIG Holdings Unlimited Company | Investment holding |
| MSDIG Holdings 2 Unlimited Company | Investment holding |
| MSD Switzerland Investments 1-4 Unlimited Company | Investment vehicles |
| MSD Ventures (Ireland) | Venture investments |
| Entity | Purpose |
|---|---|
| Merck Sharp & Dohme (Ireland) Ltd. | Listed as Bermuda-incorporated |
| Merck Sharp & Dohme (Puerto Rico) Ltd. | Bermuda holding for PR ops |
| Merck Sharp & Dohme (Singapore) Ltd. | Bermuda holding for Singapore |
| Entity | Purpose |
|---|---|
| MSD Merck Sharp & Dohme AG | Swiss operations |
| MSD International GmbH | International management |
| MSD International Finance B.V. (Swiss management) | Finance |
| MSD Innovation and Development GmbH | R&D |
| MSD Venezuela Holding GmbH | Holding |
| Entity | Purpose |
|---|---|
| MSD Asia Holdings Pte. Ltd. | Asia-Pacific holding |
| MSD Pharma (Singapore) Pte. Ltd. | Pharma operations |
| Merck Sharp & Dohme Asia Pacific Services Pte. Ltd. | Services |
| Entity | Purpose |
|---|---|
| Merck Sharp & Dohme (Puerto Rico) Ltd. | Manufacturing |
| MSD Supply Services Inc. | Supply chain |
| Entity | Purpose |
|---|---|
| Merck Sharp & Dohme B.V. | Dutch operations |
| MSD International B.V. | International holding |
| MSD International Finance B.V. | Finance |
| MSD Vietnam Holdings B.V. | Vietnam holding |
Source: SEC EDGAR, Merck 10-K EX-21 (2024), https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/exh21-subsidiarylistasof12.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0000014272 Jurisdiction: Delaware, USA Primary Offshore Hubs: Ireland, Cayman Islands, Luxembourg, Bermuda
| Entity | Purpose |
|---|---|
| Bristol-Myers Squibb Cayman Ltd. | Holding |
| Linson Investments Limited | Investment vehicle |
| Entity | Purpose |
|---|---|
| Bristol-Myers Squibb Delta Company Limited | Holding |
| Bristol-Myers Squibb Epsilon Holdings Unlimited Company | Holdings |
| Bristol-Myers Squibb Holdings Ireland Unlimited Company | Parent holding |
| Bristol-Myers Squibb International Company Unlimited Company | International ops |
| Bristol-Myers Squibb Manufacturing Company Unlimited Company | Manufacturing |
| Bristol-Myers Squibb Pharma EEIG | European operations |
| Bristol-Myers Squibb Pharmaceuticals Unlimited Company | Pharma ops |
| Bristol-Myers Squibb Services Unlimited Company | Services |
| Seamair Insurance Designated Activity Company | Insurance |
| Bristol-Myers Squibb/Pfizer EEIG | JV with Pfizer |
| Entity | Purpose |
|---|---|
| Bristol-Myers Squibb Luxembourg S.a.r.l. | Holding |
| Bristol-Myers Squibb Luxembourg International S.C.A. | International holding |
| Bristol-Myers Squibb Norway Ltd. | Norwegian ops (Luxembourg-incorp) |
| Celgene Luxembourg Sarl | Acquired Celgene holding |
| Entity | Purpose |
|---|---|
| Bristol-Myers Squibb Service Ltd. | Services |
Notable: NYT investigation (2021) revealed BMS created Irish subsidiary to reduce US tax bill by ~$1.4B. IRS characterized arrangement as "abusive" tax shelter.
Source: SEC EDGAR, BMS 10-K EX-21 (2023), https://www.sec.gov/Archives/edgar/data/14272/000001427224000044/bmy-20231231exhibit21.htm Verification: [VERIFIED] - SEC filing + NYT reporting
SEC CIK: 0001551152 Jurisdiction: Delaware, USA Primary Offshore Hubs: Ireland, Cayman Islands, Bermuda, Luxembourg, Switzerland
| Entity | Purpose |
|---|---|
| Allergan Holdings C, Ltd. | Allergan acquisition holding |
| Allergan Overseas Holding | Overseas holding |
| Pharmacyclics Cayman Ltd. | Pharmacyclics acquisition |
| Entity | Purpose |
|---|---|
| AbbVie International Holdings Unlimited Company | International holding |
| AbbVie Ireland Holdings Unlimited Company | Ireland holding |
| AbbVie Ireland Unlimited Company | Irish ops |
| AbbVie Limited | Irish entity |
| AbbVie Manufacturing Management Unlimited Company | Manufacturing mgmt |
| Allergan Equities Unlimited Company | Allergan equities |
| Allergan Holdings Unlimited Company | Allergan holding |
| Allergan Ireland Unlimited Company | Allergan Irish ops |
| Allergan Pharma Limited | Pharma ops |
| Allergan Pharmaceuticals International Limited | International pharma |
| Allergan Pharmaceuticals Ireland Unlimited Company | Irish pharma |
| Allergan Services International, Unlimited Company | Services |
| Forest Laboratories Ireland Limited | Forest Labs holding |
| Fournier Laboratories Ireland Limited | Fournier Labs |
| Pharmacyclics (Europe) Limited | European ops |
| Warner Chilcott Intermediate (Ireland) Unlimited Company | Warner Chilcott |
| Zeltiq Ireland International Holdings Unlimited Company | Zeltiq holding |
| Zeltiq Ireland Unlimited Company | Zeltiq ops |
| Entity | Purpose |
|---|---|
| Warner Chilcott Holdings Company III, Limited | Warner Chilcott |
| Warner Chilcott Limited | Warner Chilcott |
| Entity | Purpose |
|---|---|
| AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S. | Holding |
| AbbVie International S.à r.l. | International |
| AbbVie Investments S.à r.l. | Investments |
| AbbVie Overseas S.à r.l. | Overseas |
| AbbVie S.à r.l. | Main Luxembourg entity |
| Entity | Purpose |
|---|---|
| AbbVie AG | Swiss ops |
| AbbVie Biopharmaceuticals GmbH | Biopharma |
| Fastox Pharma SA | Fastox |
| ImmunoGen Switzerland GmbH | ImmunoGen |
| Pharmacyclics Switzerland GmbH | Pharmacyclics |
Source: SEC EDGAR, AbbVie 10-K EX-21 (2024), https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231xex21.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0001121404 Jurisdiction: France (20-F foreign issuer) Primary Offshore Hubs: Ireland, Luxembourg, Netherlands
| Entity | Purpose |
|---|---|
| Carraig Insurance DAC | Insurance captive |
| Genzyme Ireland Limited | Genzyme holding |
| Sanofi-Aventis Ireland Ltd | Irish ops |
| Sanofi-aventis Holdings (Ireland) Ltd | Holdings |
| Entity | Purpose |
|---|---|
| Genzyme Global Sarl | Global holding |
| Genzyme Luxembourg Sarl | Luxembourg holding |
| Le Rock Re | Reinsurance |
| Entity | Purpose |
|---|---|
| Sanofi BV | Dutch ops |
| Sanofi Foreign Participations BV | Foreign participation holding |
| Sanofi Horizon BV | Horizon holding |
| Blueprint Medicines (Netherlands) B.V. | Blueprint holding |
| Genzyme Europe B.V. | European ops |
Source: SEC EDGAR, Sanofi 20-F (2024), https://www.sec.gov/Archives/edgar/data/1121404/000112140425000010/R86.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0001114448 Jurisdiction: Switzerland (20-F foreign issuer) Primary Offshore Hubs: Ireland, Bermuda, Delaware (Novartis Capital Corp)
| Entity | Purpose |
|---|---|
| Novartis Business Services (Dublin hub) | Shared services |
| Noden Pharma DAC | Pharma acquisition |
| Entity | Purpose |
|---|---|
| Novartis Bioventures Ltd. | Venture capital fund |
| Entity | Purpose |
|---|---|
| Novartis Capital Corporation | Debt securities issuance |
Note: Novartis Capital Corporation is a finance subsidiary that issues debt securities, guaranteed by Novartis AG. Proceeds invested in marketable securities or advanced to subsidiaries.
Source: SEC EDGAR, Novartis 20-F (2025), https://www.sec.gov/Archives/edgar/data/1114448/000111444826000004/nvs-20251231.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0000901832 Jurisdiction: England and Wales (20-F foreign issuer) Primary Offshore Hubs: Ireland, Cayman Islands, Bermuda
| Entity | Purpose |
|---|---|
| AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company | IP holding, operations |
| AstraZeneca Ireland Limited | Irish ops, research collaboration |
| Alexion Pharma Holding Limited | Alexion acquisition holding |
| Alexion Pharma International Operations Limited | International ops |
| Alexion Pharma Development Limited | Development |
| Entity | Purpose |
|---|---|
| AZ Reinsurance Limited | Reinsurance |
| Gracell Biotechnologies Inc. | Acquired entity |
| Fuse Biosciences (Cayman) Limited | Investment (18.75%) |
| HBM Holdings Limited | Investment (8.78%) |
| Entity | Purpose |
|---|---|
| Alexion Bermuda Holding ULC | Alexion holding |
| Alexion Bermuda Limited | Alexion ops |
| Alexion Bermuda Partners LP | Alexion partnerships |
Notable: Alexion acquisition created multiple Bermuda entities for rare disease portfolio.
Source: SEC EDGAR, AstraZeneca 20-F EX-41 (2024), https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/R41.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0001900304 Jurisdiction: England and Wales (foreign issuer) Primary Offshore Hubs: Ireland, Singapore, Puerto Rico
| Entity | Purpose |
|---|---|
| GlaxoSmithKline (Ireland) Limited | Main Irish entity |
| GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 3) Limited | Consumer healthcare holding |
| GlaxoSmithKline Dungarvan Limited | Manufacturing |
| GlaxoSmithKline Trading Services Limited | Trading services |
| Haleon Ireland Limited | Haleon separation entity |
| Haleon Ireland Dungarvan Limited | Haleon manufacturing |
| Entity | Purpose |
|---|---|
| GlaxoSmithKline Pte. Ltd. | Singapore ops |
| GlaxoSmithKline Consumer Healthcare Pte. Ltd. | Consumer healthcare |
| GlaxoSmithKline Asia Private Limited | Asia operations |
| GSK Consumer Healthcare Singapore Pte. Ltd. | Consumer healthcare |
| Haleon Singapore Pte. Ltd. | Haleon ops |
| Entity | Purpose |
|---|---|
| GlaxoSmithKline Puerto Rico, Inc. | Manufacturing |
| ViiV Healthcare Puerto Rico, LLC | HIV medications |
| Wyeth Pharmaceuticals Company | Manufacturing |
Notable: GSK spun off Haleon consumer healthcare business in 2022, creating separate Irish holding entities.
Source: GSK Annual Report 2024, https://www.gsk.com/media/3d3fxoxd/gsk-group-company-names-and-addresses.pdf; SEC EDGAR Verification: [VERIFIED] - Company filing + SEC
SEC CIK: 0000059478 Jurisdiction: Indiana, USA Primary Offshore Hubs: Ireland, Switzerland, Puerto Rico
| Entity | Purpose |
|---|---|
| Eli Lilly and Company (Ireland) Limited | Main Irish entity |
| Eli Lilly Cork Limited | Cork operations |
| Eli Lilly Ireland Holdings Limited | Holdings |
| Eli Lilly Kinsale Limited | Kinsale manufacturing |
| Entity | Purpose |
|---|---|
| Eli Lilly Export S.A. | Export hub |
| Eli Lilly Finance, S.A. | Finance |
| Eli Lilly (Suisse) S.A. | Swiss ops |
| Eli Lilly S.A. | Swiss entity |
| Eli Lilly Vostok S.A. | Eastern Europe holding |
| Entity | Purpose |
|---|---|
| Lilly del Caribe, Inc. | Caribbean ops |
| Eli Lilly Export S.A PRSA | Puerto Rico export |
Notable: Eli Lilly Export SA (Switzerland) is the primary export hub. Ireland serves as manufacturing base.
Source: SEC EDGAR, Eli Lilly 10-K EX-21 (2024), https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/lly-20241231x10kexhibit21.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0000318154 Jurisdiction: Delaware, USA Primary Offshore Hubs: Ireland, Bermuda, Puerto Rico, Netherlands, Singapore
| Entity | Purpose |
|---|---|
| Amgen Global Technology Unlimited Company | Technology |
| Amgen Technology (Ireland) Unlimited Company | Technology |
| Horizon Therapeutics Ireland DAC | Acquired entity |
| Horizon Therapeutics Holdings Limited | Holdings |
| Horizon Therapeutics Limited | Ops |
| Pillartree Limited | Holding |
| Entity | Purpose |
|---|---|
| Amgen Technology, Limited | Technology |
| HZNP Finance Limited | Horizon finance |
| Amgen Holding No. 1 | Holding |
| ATL Holdings Limited | Holding |
| ATL Holdings II Limited | Holding |
| Entity | Purpose |
|---|---|
| Amgen Manufacturing Limited LLC | Manufacturing |
| Entity | Purpose |
|---|---|
| Amgen Global Finance B.V. | Finance |
| Amgen Worldwide Holdings B.V. | Holdings |
| Entity | Purpose |
|---|---|
| Amgen Singapore Holding Pte. Ltd. | Holding |
| Amgen Singapore Manufacturing Pte. Ltd. | Manufacturing |
Notable: Irish "Unlimited Company" designation avoids public financial statement filing requirements. Amgen has tax incentive grants in Puerto Rico through 2050 and Singapore through 2036.
Source: SEC EDGAR, Amgen 10-K EX-21 (2025), https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-ex21_2025x10xk.htm Verification: [VERIFIED] - SEC filing
SEC CIK: 0000882095 Jurisdiction: Delaware, USA Primary Offshore Hubs: Ireland, Switzerland
| Entity | Purpose |
|---|---|
| Gilead Biopharmaceutics Ireland Corporation | Main Irish entity |
| Gilead Sciences Limited | Irish ops |
| Gilead Sciences Ireland Unlimited Company | Unlimited company (privacy) |
| Janssen Sciences Ireland Unlimited Company | JV with Janssen |
Notable: Gilead transfers intangible assets from foreign subsidiaries to Ireland and the United States for tax optimization. Cork facility handles EU manufacturing and distribution. Dublin serves as drug development hub.
| Entity | Purpose |
|---|---|
| Gilead Sciences Switzerland | Swiss ops (Zug) |
Source: SEC EDGAR, Gilead 10-K (2024), https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm Verification: [VERIFIED] - SEC filing
| Company | Ireland | Cayman | Bermuda | Luxembourg | Switzerland | Singapore | Puerto Rico | Netherlands |
|---|---|---|---|---|---|---|---|---|
| Merck | ✓✓✓ | ✓✓ | ✓✓ | - | ✓✓✓ | ✓✓ | ✓✓ | ✓✓ |
| BMS | ✓✓✓ | ✓✓ | ✓ | ✓✓✓ | - | - | - | - |
| AbbVie | ✓✓✓✓ | ✓✓✓ | ✓✓ | ✓✓✓ | ✓✓ | - | - | - |
| Sanofi | ✓✓ | - | - | ✓✓ | - | - | - | ✓✓✓ |
| Novartis | ✓ | - | ✓ | - | ✓✓✓ | - | - | - |
| AstraZeneca | ✓✓✓ | ✓✓ | ✓✓ | - | - | - | - | - |
| GSK | ✓✓✓ | - | - | - | - | ✓✓✓ | ✓✓✓ | - |
| Eli Lilly | ✓✓✓ | - | - | - | ✓✓✓ | - | ✓✓ | - |
| Amgen | ✓✓✓ | - | ✓✓ | - | - | ✓✓ | ✓✓ | ✓✓ |
| Gilead | ✓✓✓ | - | - | - | ✓ | - | - | - |
Key: ✓✓✓ = Major presence (10+ entities), ✓✓ = Significant presence (3-9 entities), ✓ = Minor presence (1-2 entities)
| Company | Jurisdiction | Incentive Type | Source |
|---|---|---|---|
| Amgen | Puerto Rico | Tax grants through 2050 | 10-Q 2025 |
| Amgen | Singapore | Tax incentive through 2036 | 10-Q 2025 |
| BMS | Ireland | IP holding (NYT: $1.4B tax dispute) | NYT 2021 |
| AbbVie | Ireland | Allergan/Warner Chilcott IP | EX-21 |
| Merck | Ireland | MSD Switzerland Investments | EX-21 |
| Gilead | Ireland | Intangible asset transfers | 10-K 2024 |
| GSK | Puerto Rico | Manufacturing operations | Annual Report |
| Eli Lilly | Puerto Rico | Manufacturing operations | EX-21 |
| Type | Description | Affected Population | Scale | Source |
|---|---|---|---|---|
| Financial | Tax base erosion via offshore IP holding | US taxpayers | $1.4B (BMS case) | NYT 2021 |
| Financial | Profit shifting to low-tax jurisdictions | Multiple countries | Industry-wide | SEC filings |
| Systemic | Regulatory arbitrage through jurisdiction shopping | Global | All 10 companies | SEC filings |
[VERIFIED] All offshore structures documented are from publicly filed SEC documents (10-K, 20-F, EX-21). These are legally required disclosures.
Key Observations:
- Ireland is the dominant offshore hub (9 of 10 companies have significant Irish presence)
- Unlimited Company designation used in Ireland provides privacy (no public financial statements required)
- Cayman Islands used primarily for investment vehicles and reinsurance
- Bermuda used for holding companies and finance entities
- Switzerland used for export hubs and IP management
- Puerto Rico provides US tax territory treatment with local incentives
- Netherlands used for finance and holding structures
- What are the effective tax rates for each company's Irish entities?
- How do the "Unlimited Company" entities in Ireland handle profit repatriation?
- What is the total value of IP held in Irish subsidiaries across all 10 companies?
- Are there additional offshore entities not required to be listed in EX-21 (below 10% significance threshold)?
Verification level: FULLY VERIFIED Confidence: HIGH Last updated: 2026-08-22
Data Sources:
- SEC EDGAR (primary)
- Company annual reports
- NYT investigative journalism (BMS tax case)
Limitations:
- EX-21 only lists "significant" subsidiaries (10% threshold)
- Ownership chains between entities not disclosed
- Financial data for individual entities not available in these filings
- Some entities may have been dissolved or renamed since filing dates